Botulinum toxin type A for the treatment of the spastic equinus foot in cerebral palsy.

作者: Eduardo S. Cardoso , Bernardo M. Rodrigues , Marcelo Barroso , Carla J. Menezes , Rita S. Lucena

DOI: 10.1016/J.PEDIATRNEUROL.2005.08.010

关键词: Physical medicine and rehabilitationSpasticitySpasticTizanidineGait analysisRandomized controlled trialPhysical therapyBotulinum toxinBaclofenCerebral palsyMedicine

摘要: Muscle overactivity, one of the cardinal features spasticity, is a common sequel cerebral palsy. In this group patients spasticity responsible for several limitations that interfere with gait, causing variable functional disability. Drugs such as baclofen, tizanidine, or benzodiazepines, even definitive treatments orthopedics neurosurgeries are generally prescribed uncertain results. The use botulinum toxin type A has been frequently suggested treatment spastic equinus foot in palsy, but few studies adequate methodology support idea. present paper reviews and summarizes data published double-blind, randomized clinical trials to assess, meta-analysis, if an caused by results reveal statistical superiority over placebo on gait improvement, tested using Physician Rating Scale Video Gait Analysis (Peto odds ratio = 3.99, 95% confidence interval 2.20-7.22) foot. also presented better subjective assessment than 3.49, 1.50-8.12). Adverse events were more observed after A, they considered mild self-limited.

参考文章(18)
L Andrew Koman, James F Mooney III, Beth Paterson Smith, Francis Walker, Judith M Leon, BOTOX Study Group, Botulinum Toxin Type A Neuromuscular Blockade in the Treatment of Lower Extremity Spasticity in Cerebral Palsy: A Randomized, Double-blind, Placebo-controlled Trial Journal of Pediatric Orthopaedics. ,vol. 20, pp. 108- 115 ,(2000) , 10.1097/01241398-200001000-00022
Suzanne K. Campbell, Physical Therapy for Children ,(2000)
Alejandro R. Jadad, R.Andrew Moore, Dawn Carroll, Crispin Jenkinson, D.John M. Reynolds, David J. Gavaghan, Henry J. McQuay, Assessing the quality of reports of randomized clinical trials : is blinding necessary? Controlled Clinical Trials. ,vol. 17, pp. 1- 12 ,(1996) , 10.1016/0197-2456(95)00134-4
Tai Ryoon Han, Moon Suk Bang, Jae Young Lim, Bo Hyeon Yoon, In Won Kim, Risk factors of cerebral palsy in preterm infants. American Journal of Physical Medicine & Rehabilitation. ,vol. 81, pp. 297- 303 ,(2002) , 10.1097/00002060-200204000-00011
David H Sutherland, Kenton R Kaufman, Marilynn P Wyatt, Henry G Chambers, Scott J Mubarak, Double-blind study of botulinum A toxin injections into the gastrocnemius muscle in patients with cerebral palsy Gait & Posture. ,vol. 10, pp. 1- 9 ,(1999) , 10.1016/S0966-6362(99)00012-0
L Andrew Koman, James F. Mooney, Beth P. Smith, Amy Goodman, Theresa Mulvaney, Management of spasticity in cerebral palsy with botulinum-A toxin: report of a preliminary, randomized, double-blind trial. Journal of Pediatric Orthopaedics. ,vol. 14, pp. 299- 303 ,(1994) , 10.1097/01241398-199405000-00005
S. C. Love, J. P. Valentine, E. M. Blair, C. J. Price, J. H. Cole, P. J. Chauvel, The effect of botulinum toxin type A on the functional ability of the child with spastic hemiplegia a randomized controlled trial European Journal of Neurology. ,vol. 8, pp. 50- 58 ,(2001) , 10.1046/J.1468-1331.2001.00038.X
L. Andrew Koman, James F. Mooney, Beth Smith, Amy Goodman, Theresa Mulvaney, Management of cerebral palsy with botulinum-A toxin: preliminary investigation. Journal of Pediatric Orthopaedics. ,vol. 13, pp. 489- 495 ,(1993) , 10.1097/01241398-199307000-00013